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ABSTRACT
Natural killer (NK) cells constitute the first line of defense against viruses and 
cancers cells. Epstein–Barr virus (EBV) was the first human virus to be directly 
implicated in carcinogenesis, and EBV infection is associated with a broad spectrum 
of B cell lymphomas. How NK cells restrict EBV-associated oncogenesis is not 
understood. Here, we investigated the efficacies and mechanisms of distinct NK cell 
subsets from tonsils, the portal of entry of EBV, in limiting EBV infection in naïve, 
germinal center-associated and memory B cells. We found that CD56bright and NKG2A 
expression sufficiently characterizes the potent anti-EBV capacity of tonsillar NK cells. 
We observed restriction of EBV infection in B cells as early as 18 hours after infection. 
The restriction was most efficient in naïve B cells and germinal center-associated B 
cells, the B cell subsets that exhibited highest susceptibility to EBV infection in vitro. 
IFN-γ release by and partially NKp44 engagement of CD56bright and NKG2A positive NK 
cells mediated the restriction that eventually inhibited B-cell transformation. Thus, 
harnessing CD56brightNKG2A+ NK cell function might be promising to improve treatment 
strategies that target EBV-associated B cell lymphomas.
INTRODUCTION
Epstein Barr virus (EBV) has been strongly associated 
with B-cell cancers including endemic Burkitt’s lymphoma, 
Hodgkin’s disease, and post-transplant lymphoproliferative 
disease (PTLD) [1–3]. Immunocompromised hosts are 
at highest risk for EBV-associated B cell malignancies 
whereas the vast majority of immunocompetent individuals 
do not develop such pathology and remain healthy 
EBV carriers after primary infection, which is mainly 
acquired in childhood (2). Nevertheless, after Infectious 
Mononucleosis, i.e. symptomatic primary EBV infection, 
there is a 20-fold increased risk to develop Hodgkin 
lymphoma [4]. Of further note, EBV-associated Burkitt’s 
lymphoma, Hodgkin’s lymphoma as well as PTLD all 
derive from germinal center cells and are thereby linked 
to distinct differentiation stages of B cells in secondary 
lymphoid organs [5]. While the lack of EBV-specific 
immune control is a well-recognized risk factor for EBV-
associated B cell tumors (2, 3), the factors that prevent the 
development of EBV-associated malignancies or allow 
malignant transformation in immunocompetent EBV 
carriers remain incompletely understood, especially those 
of innate immunity. 
Innate immune reactions and their balanced 
surveillance build the first line of defense against 
infectious agents and cancer cells. If this balance is 
skewed, severe infections or neoplasms may develop. 
Natural killer (NK) cells were first described and named 
based on their innate ability to kill virus-infected cells or 
cancer cells without pre-activation [6, 7]. In the peripheral 
blood, two main NK cell subsets have been described 
(reviewed in [8]). The CD56dim NK cells are innate 
cytotoxic killer cells, whereas CD56bright cells produce an 
array of cytokines such as IFN-γ, TNF-α, GM-CSF. After 
their precursor development in the bone marrow NK cells 
migrate to secondary lymphoid organs (SLOs) including 
tonsils, the portal of entry of EBV, to mature and only 
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after maturing fully egress back to the peripheral blood 
to patrol the human body against intruders or malignantly 
altered cells [9, 10]. Notably, CD56bright NK cells are 
the most advanced differentiation stage of mature NK 
cells in the tonsils, whereas they are the least advanced 
differentiation stage of mature NK cells circulating in 
the peripheral blood [11]. It is long documented that 
NK cells are a crucial component of immune control 
of EBV infection and tonsillar CD56bright NK cells have 
been found to restrict EBV-induced transformation 
more potently than tonsillar CD56dim NK cells [12]. We 
have recently identified a distinct subset of tonsillar and 
blood CD56bright NKG2A+CD94+CD54+CD62L− NK 
cells, which mediates restriction of EBV-induced B cell 
transformation after established EBV-infection [13]. 
Subsequently, NK cells were shown to control EBV 
infection in a “humanized” mouse model reconstituted 
with a human immune system. In this model a subset of 
NK cells, namely NKG2A+ NK cells accumulated in the 
peripheral blood 4 weeks after primary EBV infection, 
before the onset of infectious mononucleosis (IM, acute 
symptomatic EBV infection) like symptoms, preceding 
the IM characteristic CD8+ T cell expansion. If NK cells 
were depleted the experimental animals got sick more 
rapidly and more severely, with worse IM symptoms and 
a significantly higher tumor load [14]. In addition, we 
found recently that CD56dimNKG2A+ NK cells accumulate 
in the peripheral blood of acutely EBV-infected pediatric 
patients manifesting IM [15]. Even 6 months after IM 
expansion of this specific NK cell subset prevailed that 
preferentially targets B cells with replicating EBV. 
Here, we expanded our previous work (13, 17) 
by investigating the efficacies and mechanisms of 
human tonsillar NK cell subsets to restrict early EBV 
infection. To this end, we compared and characterized 
the potency of tonsillar CD56brightNKG2A+ NK cells 
vs. other NK cell subsets (i) in restricting EBV-induced 
B cell transformation in vitro; (ii) in restriction of early 
EBV infection in B cells; and characterized (iii) the 
CD56brightNKG2A+ NK cells, i.e. the distinct anti-EBV NK 
cell subset in detail towards sorted autologous tonsillar B 
cell subsets, i.e. naïve, germinal center-associated, and 
memory B cells, respectively. 
RESULTS 
Tonsillar CD56bright NKG2A+ NK cells restrict 
outgrowth of EBV-infected B cells more 
efficaciously than CD56bright NKG2A− and 
CD56dim NK cells
We previously demonstrated that human tonsillar 
CD56brightNKG2A+CD94+CD54+CD62L− NK cells, which 
produce high levels of IFN-γ, potently restrict EBV-
transformed B cells in vitro [13]. After recent descriptions 
of accumulation of NKG2A+ NK cells during acute 
primary EBV infection in a humanized mouse model, 
with increased tumor rates after NK depletion [14] and in 
peripheral blood of IM patients [15], we were intrigued 
to determine the EBV restriction capacity of tonsillar 
CD56brightNKG2A+ compared to other tonsillar NK cell 
subsets in our previously described transformation 
restriction assay [13].
Thus, we first determined the potency of NK 
cells defined by CD56 and NKG2A expression 
(Gating/sorting strategy Figure 1A and 1B) to restrict 
transformed B cells after established EBV infection as 
described previously [13]. Briefly, we sorted tonsillar 
CD56brightNKG2A+ NK cells, CD56brightNKG2A− NK cells, 
and CD56dim NK cells and co-cultured these subsets with 
autologous B cells. We quantified restriction of B cell 
transformation normalized to frequencies of infected B 
cells in cultures without NK cells with the formula used 
before [13]: Restriction = (100 − (% transformed B cells 
in co-culture/% transformed B cells without NK) ×100). 
We found that CD56brightNKG2A+ NK cells 
inhibit EBV-induced B cell transformation greater 
than 6-fold more than their counterparts (p = 0.0005 
for CD56brightNKG2A− NK cells and p = 0.0002 for 
CD56dim NK cells, respectively) (Figure 1C). In addition, 
CD56brightNKG2A+ readily produced IFN-γ upon IL-12 
stimulation (10 ng/ml for 18 hours) (Figure 1D), another 
hallmark of the tonsillar anti-EBV NK subset identified by 
us previously [13].
Thus, CD56bright and NKG2A expression sufficiently 
define phenotypically the potent anti-EBV NK subset, 
which is potent in IFN-γ production. We use these 
phenotype markers throughout this study to identify and 
functionally characterize this NK cell subset further. 
Tonsillar naïve B cells and centrocytes are more 
susceptible to EBV infection than memory B cells
Successively, we determined if the superior 
restriction capacity of CD56brightNKG2A+ NK cells 
compared to other NK cell subpopulations is detectable 
already early after infection with EBV. To this end, we 
adapted the B cell transformation assay and co-cultured 
flow-sorted autologous B cells with the distinct tonsillar 
NK cell subsets for 72 hours. As we used the recombinant 
GFP-EBV virus [16], we could determine the extent 
of B cell infection by flow cytometry measuring the 
frequency of GFP expressing B cells. By flow-sorting 
the B cell subsets before infection we ensured that any 
potential subset defining marker/ receptor changes upon 
culture and/or infection would not influence the analysis 
of the subsets susceptibility. Thus, we determined the 
true susceptibility of distinct B cell differentiation stages 
in vitro. We readily detected the potent CD56brightNKG2A+ 
NK cell-mediated restriction of EBV 3 days (72hours) 
after infection (Figure 2). CD56brightNKG2A+ NK cell 
restricted EBV-infected B cells greater than 3-fold more 
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than CD56brightNKG2A− NK cells (p = 0.002) and greater 
than 30-fold more than CD56dim NK cells (p = 0.0001), 
respectively (Figure 2).
EBV-associated cancers are derived of germinal 
center B cells, i.e. centrocytes [5, 17, 18]. Which tonsillar 
B cell subsets are most susceptible to EBV infection 
in vitro remains debated and seems to depend on the 
experimental approach [5, 19–22]. Consequently, to 
analyze the potency of CD56brightNKG2A+ NK cells 
towards tonsillar B cell differentiation stages as intended, 
we first determined the susceptibility to EBV infection of 
the distinct tonsillar B cell differentiation stages in vitro 
without NK cells present, analyzing sorted naïve B cells, 
centroblasts, centrocytes and memory/plasmablasts B 
cells, respectively (Gating/Sorting strategy: Figure 3A). 
For all sorts, we grouped together memory B cells 
and plasmablasts (memory/plasmablasts, defined in 
Figure 3B). The distinct B cell differentiation subsets were 
sorted from EBV-naïve donors’ tonsillar mononuclear cells 
(TMCs), inoculated with recombinant GFP expressing-
EBV [16], and the frequency of EBV-infected B cells was 
determined by flow cytometry after 72 hours. Frequencies 
of all B cell subsets (Figure 3C), as well as for the sorted 
subsets (Figure 3D) were recorded. After 72 hours of EBV 
inoculation, we found that naïve B cells and centrocytes 
are most susceptible to EBV infection of all analyzed 
Figure 1: Identification and characterization of human CD56brightNKG2A+ NK cells and restriction of EBV in B 
cells. (A) Basic gating for all tonsillar and peripheral samples throughout this manuscript (representative example of PBMCs is shown); 
(B) Gating for CD56brightNKG2A+ and compared NK cell subsets (representative example of PBMCs is shown); (C) Restriction of EBV 
transformation of B cells after established EBV infection in B cells by tonsillar CD56brightNKG2A+ NK cells compared to other subsets 
(6 donors); (D) IFNγ production induced by overnight cytokine stimulation in different tonsillar NK subsets (3 donors); Restriction = 
(100 − (% transformed B cells in co-culture/% transformed B cells without NK) ×100); Data represent three independent experiments. All 
error bars represent SEM. p values depicted were calculated with two-tailed student’s t test, or (1D) regular ANOVA corrected for multiple 
comparison testing by Tukey correction.
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differentiation stages (Figure 3E). Subsequently, we 
analyzed the increased susceptibility of naïve B cells 
and centrocytes towards EBV infection at very early 
time-points from 18 hours until 72 hours after infection. 
We detected the superior infection of naïve B-cells and 
centrocytes compared to centroblasts and memory/
plasmablasts already at 18 hours after infection, and the 
fold-changes increased over time (data not shown).
To determine if these differences were due to 
differential expressions of known EBV entry receptors, 
we analyzed expression of CD21 (Figure 3F), CD35 
(Figure 3G) and HLA-DR (Figure 3H) on the B cell subsets. 
We did not detect differential expression by the subsets in 
line with the susceptibility differences (Figure 3F, 3G, 3H). 
Hence, we show here that tonsillar naïve B cells 
and centrocytes, which are undergoing or will undergo 
the germinal center reaction, are more susceptible to 
EBV infection as compared to centroblasts and higher 
differentiation stages of B lineage cells, and this is not 
dependent on differential expression of known entry 
receptors.
Tonsillar naïve B cells and centrocytes are 
more susceptible to CD56bright NKG2A+ NK 
cell-mediated restriction of EBV infection than 
higher differentiated B-cells
To determine if distinct pre-, post- or germinal center 
B-cell subsets are restricted at similar, or different levels 
by CD56bright NKG2A+ NK cells, we next analyzed for the 
first time the potency to restrict EBV infection in distinct 
differentiation stages of B cells after 72 hours. CD56bright 
NKG2A+ NK cells were more efficient in inhibiting the 
outgrowth of EBV-infected B cell subsets as compared 
to CD56brightNKG2A− NK cells, and CD56dim NK cells for 
each subset investigated (Figure 4A). CD56brightNKG2A+ 
NK cell-mediated restriction of EBV infection was most 
efficient for naïve B cells and centrocytes compared 
to centroblasts and memory B cells (Figure 4B), while 
memory/plasmablasts B cells were least susceptible. 
In the same assay, B cells showed significantly higher 
frequencies of live cells in co-cultures of total B cells with 
CD56brightNKG2A+ NK cells compared to cultures without 
NK cells, whereas the presence of CD56brightNKG2A− or 
CD56 dim NK cells did not alter the frequency of live 
B cells (Figure 4C). When B cell differentiation stages 
were sorted before infection both co-cultures with 
CD56brightNKG2A+ and CD56brightNKG2A− show higher 
frequencies of live B cells than cultures without NK cells, 
but only in naïve B cells and centrocytes. Furthermore, 
we observed potent inhibition of EBV-infected B cell 
outgrowth by CD56bright NKG2A+ NK cells already 
18 hours after EBV infection and it increased over time 
for all B cell subsets investigated (Figure 5).
In conclusion, we show here for the first time that 
CD56bright NKG2A+ NK cells efficiently inhibit outgrowth 
of all tonsillar EBV-infected B cell differentiation subsets., 
being superior in their The restriction of EBV-infected 
naïve B cells and centrocytes was superior, compared to 
higher differentiation stages of tonsillar B cells. 
Figure 2: Differences in restriction of early EBV infection in B cells by autologous CD56brightNKG2A+ NK cells compared 
to other tonsillar NK subsets. Restriction of transformation assay was adapted to analyze restriction of early EBV infection after 72 h 
post infection, i.e. before transformation is induced. EBV GFP tagged virus was used. Frequency of EBV positive cells was determined by 
frequency of GFP positivity. Restriction of EBV infection was calculated by formula: Restriction = (100 − (% infected cells in co-culture/ 
% infected cells without NK) ×100). Data represent three independent experiments, with a total of 3 donors. All error bars represent SEM. 
p values depicted were calculated with two-tailed student’s t test.
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CD56bright NKG2A+ NK cells restrict outgrowth of 
tonsillar EBV-infected B cells through IFN-γ and 
NKp44
To determine the mechanism by which CD56bright 
NKG2A+ NK cells inhibit outgrowth of tonsillar 
EBV-infected B cells, we inhibited activating natural 
cytotoxicity receptors with established [23–28] blocking 
antibodies specific for NKp30, and NKp44, interaction 
with MHC class I-recognizing inhibitory receptors with 
an established [29–31] blocking antibody specific for 
HLA-A, -B, and -C molecules and IFN-γ-mediated effects 
with antibodies specific for the IFN-γ and its receptor 
(Figure 6A). Restriction of EBV-infected B cells was 
determined 72 hours after infection as described above. 
Both blocking either IFN-γ or IFN-γ receptor (IFN-γR) 
abrogated the CD56brightNKG2A+ NK cell-mediated 
restriction of EBV. NKp44-specific antibody blockade 
Figure 3: Flow-sorted human germinal center and pre-germinal center B cell subsets show higher susceptibility to 
EBV than post-germinal center subsets. (A) Human tonsillar B cell subset gating; (B) Definition of human tonsillar B cell subsets 
for sorting experiments, higher maturation stages were grouped together as depicted; (C) Frequencies of all major tonsillar B cell subsets 
(4 donors, 3 experiments); (D) Frequency of the four investigated sorting subsets in tonsils (4 donors, 3 experiments); (E) Susceptibility of 
defined sorted tonsillar B cell subsets to EBV infection (72 h) (8 donors, 6 experiments). Frequency of EBV entry receptors CD21 positive 
(F), CD35 positive (G), or HLA-DR positive (H) cells in tonsillar B cell subsets (each 4 donors, 3 experiments); Frequency of all error bars 
represent SEM; p values depicted were calculated with two-tailed student’s t test.
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inhibited EBV restriction, whereas blockade with NKp30 
and HLA-ABC-specific antibodies did not show any 
significant effects. Next, we added low concentrations 
(5 pg/ml) of established [23, 24] exogenous IFN-γ 
to tonsillar B cells at various time points after EBV 
inoculation and monitored its efficacy to inhibit B cell 
transformation. IFN-γ alone potently induced restriction 
of EBV-infected B cell outgrowth, being most potent at 
days 3 and 4 after infection (Figure 6B). We included a 
dosage curve for IFN-g in the Supplementary Figure S2. 
Of note, due to IFN-g toxicity in higher concentrations, 
overall survival decreases markedly in cultures with 
higher concentrations and thus restriction in higher doses 
might be underestimated.
Taken together, CD56brightNKG2A+ NK cells restrict 
the outgrowth of tonsillar EBV-infected B cells through 
IFN-γ release and the natural cytotoxicity receptor 
NKp44 partially contributes to this effect and IFN-γ can 
restrict EBV even after infection and/or transformation is 
established.
DISCUSSION 
In this study we analyzed the innate NK cell 
response towards EBV infection in tonsillar B cells i.e. 
at the site of the first contact of EBV with B cells upon 
in vivo infection. We identified tonsillar CD56brightNKG2A+ 
NK cells as the main effector NK cell subset in restricting 
outgrowth of EBV-infected tonsillar B cells at the viral 
portal of entry. CD56brightNKG2A+ NK cells exhibited 
restriction as early as 18 hours after infection, and this 
was most efficient against EBV-infected naïve B cells 
and centrocytes, i.e. those B cell differentiation subsets 
we determined to be most susceptible to EBV infection. 
This process was predominantly mediated through IFN-γ 
release, and partially by the activating receptor NKp44. 
Our results may have implications for the use of NK cell 
subsets in novel treatments against EBV-associated B-cell 
malignancies.
We show here for the first time that CD56brightNKG2A+ 
NK cells from palatine tonsils are the most efficient 
tonsillar NK cell subset in impairing the outgrowth of 
EBV-infected B cells. In the past, only T cells were 
believed to play the crucial role in controlling established 
EBV infection [2]. Recent studies, however, provided 
increasing evidence that NK cells are contributing to the 
immune control [12, 13]. In particular, it was shown that 
NKG2A+ NK subsets accumulate in vivo in humans with 
infectious mononucleosis [15] and in experimental animal 
models such as humanized mice [14]. CD56brightNKG2A+ 
NK cells are precursors of CD56dimNKG2A+ cells, the 
NKG2A+ NK subset that accumulates in peripheral blood 
of patients with acute infectious mononucleosis [15]. 
This may suggest that the tonsillar CD56brightNKG2A+ 
NK cells differentiate into CD56dimNKG2A+ cells upon 
encounter of EBV. During infection with the human 
cytomegalovirus (CMV) [32], by contrast, NKG2C+ NK 
cells are expanded over long time periods in the peripheral 
Figure 4: CD56brightNKG2A+ NK cells restrict EBV most potently in germinal center and pre-germinal center tonsillar 
B cell subsets. (A) CD56brightNKG2A+ mediated restriction of EBV-infected B cell subsets compared to effects of CD56brightNKG2A− and 
CD56dim NK cells (8 donors, 6 experiments); (B) CD56brightNKG2A+-mediated restriction in EBV-infected B cell subsets after 72 h (8 donors, 
6 experiments); Differences in survival in cultures without NK cells present and co-cultures of total B cells (6 donors, 4 experiments) 
(C) and of sorted B cell subsets (6 donors, 4 experiments) (D), measured by frequency of Live/Dead cell staining negative population at 72 
h. All error bars represent SEM. p values depicted were calculated with two-tailed student’s t test. n.s.- not significant.
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blood, which in parallel acquired CD57 [33]. NKG2C+ cell 
expansions have also been described in infections with 
Hantavirus [34], Chikungunya virus [35], HIV [36, 37], 
and Kaposi Sarkoma in AIDS patients [38]. All of these 
expanded NK cell subsets represent high maturation stages 
and include classical killer cells and potent mediators of 
antibody-dependent cytotoxicity (ADCC) [39]. These high 
maturation stages of NK cells have been found to be potent 
effectors of the NK cell-mediated regulatory “rheostat” 
effects, protecting the viral niche by tuning down CD4 
T cells, which regulate antiviral CD8 T cells [40]. Thus, 
NKG2A+ NK cell accumulation appears to be fairly specific 
for EBV. Our finding that tonsillar CD56brightNKG2A+ NK 
cells are the most efficient NK cell subset in restricting 
EBV strongly suggests that the CD56dimNKG2A+ NK cells 
observed in peripheral blood from patients with acute 
infectious mononucleosis may derive from their precursors 
in the portal of entry of EBV upon primary infection with 
this virus.
Our observation that tonsillar NKG2A+ NK cells 
predominantly elicit the restriction of EBV might be very 
remarkable in the light that subsequent to IM the risk to 
develop EBV-positive Hodgkin’s lymphoma is 20-fold 
increased [4]. Thus, failure to efficiently control the 
acute primary EBV infection mirrored by an exuberant 
cytotoxic T cell response as in IM seems to predispose to 
EBV-associated B-cell cancer. Indeed, children younger 
than 5 years of age, who very rarely develop IM and 
EBV-associated B-cell cancer [2], have higher numbers 
of NKG2A+ NK cells in peripheral blood [41, 42]. In 
line with the strongly reduced frequencies of immature 
NKG2A+ NK cells found in adults [41, 42], we previously 
have shown that CD56brightNKG2A+CD94+CD54+CD
62L− NK cells are much less frequent in the peripheral 
blood of adults than of children [13]. Here we show 
that NKG2A+ NK cells in tonsils are the distinct NK 
cell subset exhibiting superior control of EBV-infected 
B cells. Most notably, we show that this subset is most 
potent against EBV-infected naïve B-cells which need 
to undergo the germinal center reaction and against 
centrocytes, the main cellular origin of EBV-associated 
B cell tumors [5]. Taken together, if EBV infection is 
deferred to later in life, the numbers of CD56bright NK 
cells of potent anti-EBV CD56brightNKG2A+ NK cells 
present in tonsils to immediately contain the infection 
of the B cells might be too low so that the exuberant IM 
Figure 5: Early restriction of EBV by human CD56brightNKG2A+ NK cells over time: Potency of CD56brightNKG2A+ 
mediated EBV restriction at different time points in flow sorted B cell differentiation stages compared to effects of 
CD56brightNKG2A− NK cells. Data represent four independent experiments, with a total of 8 donors. All error bars represent SEM. 
p values depicted were calculated with two-tailed student’s t test.
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reaction is needed to control primary EBV infection. The 
transiently uncontrolled EBV infection of the naïve and 
germinal center B cells might predispose to increased 
somatic hypermutation and subsequently enhanced risk for 
“seeding” and developing cancer. We hypothesize that if 
CD56brightNKG2A+ NK cell mediated control is lacking or 
malfunctioning, cancer might develop driven by the strong 
transforming capacities of EBV at primary infection. This 
would be a potential explanation for the increased risk of 
EBV-associated cancers after primary EBV infection also 
whilst on iatrogenic immunosuppression, such as PTLD.
Equally important, our findings unprecedentedly 
demonstrate that CD56brightNKG2A+ NK cells restrict 
outgrowth of EBV-infected B cells dependently of IFN-γ, 
partially dependently of NKp44, and independently of 
NKp30 and HLA ABC. It was shown before, that NK cells 
mediate restriction of EBV-induced B cell transformation 
largely, but not completely, via IFN-γ [12, 13]. NK cell 
effector functions are controlled by germline-encoded 
activating and inhibitory receptors. If more activating 
signals are received due to high expression of activating 
NK cell receptor ligands or loss of inhibitory NK cell 
receptor ligands, NK cells are unleashed. This prompted 
us to explore whether such activating signals are involved 
in the outgrowth restriction. Therefore, we additionally 
functionally explored the restriction role of the activating 
receptors NKp44, NKp30, and NKG2D [43]. Indeed, we 
found reduction of restricting activity only for NKp44 
(Figure 6A). Notably, only few blood NK cells express 
NKp44, whereas tonsillar NK cells express it more 
abundantly (Supplementary Figure S1). Thus, our data 
are in line with former studies, but document for the 
first time IFN-γ as the main mediator and of NKp44 as 
partial mediator early in infection resulting in restriction 
of outgrowth EBV-infected B cells. 
Notably, we show that exogenous IFN-γ potently 
restricts EBV-induced transformation, even at low 
concentrations and even if added up to 10 days after 
in vitro infection (latest time point analyzed) to the B cell 
cultures. In 1985, IFN-γ was found to be potent against 
EBV up to 3–4 days after infection, whereas IFN-α and -β 
were found to be antivirally effective only within the first 
24 hours after infection [44]. In contrast to our finding, 
in their assay of B cell outgrowth Lotz et al. more than 
20 years ago found no relevant restriction following 
treatment more than 4 days after infection. They stated 
that their finding might be dose and assay dependent. 
Consequently, we suggest that the findings at variance 
might be explained by methodological differences and 
their sensitivities. Of further note, IFN-γ reached in 
our study the peak of restriction capacity with addition 
3–4 days after infection. In this study, we added NK 
cells at the time of inoculation in physiological numbers 
and the restriction was mainly IFN-γ dependent. Thus, 
we might likely underestimate the anti-EBV strength of 
CD56brightNKG2A+ NK cells in our in vitro experimental 
set-up as these regulators might still be recruited to the 
sight of infection in higher numbers in vivo after initial 
infection. 
One limitation of the present study is that we have 
not formally shown that NKG2A from tonsillar NK cells 
binds to HLA-E. Nevertheless, there is ample experimental 
evidence regarding the specificity of NKG2A and HLA-E 
binding [45–48]. The inhibitory CD94/NKG2A receptor 
belongs to the C-type lectin family of proteins [45]. It 
binds to the non-classical MHC I molecule HLA-E [46] 
Figure 6: CD56brightNKG2A+-mediated restriction of EBV depends strongly on IFN-γ and partially on NKp44. (A) 
Blocking of NK cell receptors and IFN-γ or IFN-γ receptor (72 h) (8 donors, 4 experiments); (B) Low dose exogenous IFN-γ assay to define 
time points when EBV restriction is potent (6 donors, 4 experiments). All error bars represent SEM; p values depicted were calculated with 
two-tailed student’s t test. 
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and results in an inhibitory signal. Patients with acute 
hepatitis B virus infection were found to have increased 
numbers of NKG2A+ NK cells in their peripheral blood 
and blocking CD94/NKG2A interaction with HLA-E 
was found to promote clearance of hepatitis B virus very 
efficiently in mice [47]. In some cases, e.g., in some 
cancer cells, HLA-E is upregulated to evade attack of the 
anti-cancer NK cells, and very recently a “humanized” 
blocking antibody has been shown to potently unleash 
their potential against human leukemic cells and EBV 
cell lines in engrafted mice and rescue them from disease 
progression [48]. In line with this, Monalizumab by 
Innate Pharma/AstraZeneca (London) is an anti-NKG2A 
antibody infusion currently in phase 1 and 2 trials against 
head & neck cancers. This antibody therapy blocks the 
inhibition signal of the NKG2A receptor, and thereby 
unleashes those cells towards cancer cells, which can 
express high levels of the NKG2A ligand HLA-E. Our 
data indicate that NKG2A blockade could be harnessed 
against EBV positive B cell cancers.
In conclusion, we identified human tonsillar 
CD56brightNKG2A+ NK cells to restrict outgrowth of 
autologous EBV-infected tonsillar B cells, preferentially 
targeting germinal center or pre-germinal center (naïve) B 
cell subsets. Germinal center B cells are strongly associated 
with EBV-associated cancers [5, 17, 18].  Therefore, 
unleashing and harnessing CD56brightNKG2A+ NK cell 
function by e.g. either by blocking HLA-E on tumor cells, 
or by blocking NKG2A+ on NK cells or administering 
cytokines such as IL-15 which expand these NK cell subsets 
in the patients, might have a strong therapeutic merit in 
limiting and fighting EBV-associated tumor formation.
MATERIALS AND METHODS
Ethical approval for human samples
All studies were conducted in accordance with the 
guidelines of the World Medical Association’s Declaration 
of Helsinki. All studies were reviewed and approved by 
the institutional review board protocol KEK-StV-Nr. 
19/08 through the cantonal ethical committee of Zurich, 
Switzerland. After informed consent of the donors legal 
guardians blood and tonsil samples were received for 
study purposes. The Zürcher Blutspendedienst SRK, 
Switzerland, who had also previously approved all studies, 
provided blood concentrates.
Reagents
The following anti-human Abs were used in 
this study: 7-AAD PerCP, CD8 PE, CD16 APC-Cy7, 
CD21 APC, CD38 PE, CD56 PE-Cy7, DNAM-1 FITC, 
GM-CSF PerCP/Cy5.5, IFN-γ APC, Ki 67 FITC (all BD 
Biosciences); CD3 Pacific Blue (Life Technologies); CD4 
APC, CD19 PE, (eBioscience); CD20 PE-Cy5, CD27 
APC-Cy7, IgD PE-Cy7, NKp44 APC (BioLegend); 
CD158a, h PE-Cy5.5, CD158b1/b2, j PE-Cy5.5, CD158a, 
h APC, CD158b1/b2, j APC, CD159a (NKG2A) PE, 
CD159a (NKG2A) APC (Beckmann Coulter); hIL-12 Rß 
PerCP (R&D Systems). Live cells were distinguished using 
the LIVE/DEAD Fixable Aqua Dead Cell Stain Kit (Life 
Technologies). Following endotoxin free recombinant 
human (rh) cytokines were used: rhIL-12 (R&D Systems), 
rhIL-2 (PeproTech), and rhIL-15 (Sigma).
EBV preparation, cell culture and serostatus of 
donors
Rekombinant GFP-tagged EBV was produced in 
the B95-8 bacmid use [16] carrying 293-HEK cells in 
10 cm dishes by standard 4-h Metafectene Pro (Lucerna) 
transfection according to the manufacturer’s protocol. 
Briefly, after selction by 0.1% Hygromycin in the medium 
to 70% confluency, plasmids (p509 carrying BZLF-1 [49]; 
and p2670 carrying BALF-4, gp110 [50]) were preincubated 
20 min at room temperature with Metafectene and then 
added to the cell dishes and incubated 4 h in antibiotic-
free medium. Then, RPMI 1640 + 10% FCS medium was 
replaced with gentamicin-containing RPMI 1640 + 10% 
FCS medium. After 3 days supernatant was harvested 
and filtered through 0.45-µm filters, and EBV was further 
purified and concentrated by ultracentrifugation at 30,000g 
for 2 h at 4°C, resuspended carefully in RPMI 1640, and 
titered on Raji cells [51] as described previously [13]. Titers 
were calculated in Raji infectious units (RIU) and Titers of 
0.5RIU were used for all experiments. 
All cells and cell lines were cultured at 37°C, 5% 
CO2 if not noted otherwise. 
For all tonsil samples serology for EBV was 
determined with the ImmunoDot Mono G Kit (GenBio) 
on blood plasma.
NK and B cell purification and culture
To obtain Peripheral Blood Mononuclear Cells 
(PBMCs), blood samples from under-age tonsillectomy 
patients of the University Children’s Hospital Zurich or 
from adult donors by the Zürcher Blutspendedienst SRK 
were received within 18 hours after blood withdrawal. 
Single cell suspension from tonsils were obtained as 
described before [13]. TMCs and PBMCs were then 
isolated by Ficoll-Paque PREMIUM (GE Healthcare) 
gradient centrifugation and cryopreserved.
After thawing TMCs or PBMCs cells were washed 
in PBS. Cell suspension was filtered through a 70 µm 
nylon cell strainer to remove debris and dead cells. The 
various cell types were purified from PBMC or TMC 
samples via fluorescence-activated cell sorting (FACS) 
or magnetic cell separation (MACS) for separating B 
and NK cells and their subsets as indicated in the figure 
legends.
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For some experiments, total B cells were purified 
by positive selection kit human CD20 MicroBeads 
on the QuadroMACS™ Separator and corresponding 
MACS MultiStand (Miltenyi biotec), as described in the 
manufacturer’s protocol. The CD20 negative fraction 
was consecutively used for isolation of total NK cells, 
which were extracted via the human NK Cell Isolation kit 
through negative selection according to the manufacturer’s 
protocol (Miltenyi biotec).
For all other experiments, cells and subsets were 
isolated via flow sorting on the Aria III (BD Biosciences). 
Briefly, cells were suspended in 2% hi-FBS PBS before 
sorting into B cells (CD3− CD20+) and NK cells (CD3− 
CD56+) on the BD FACSAria III through an 85 µm 
nozzle for 4-way purity. In a second step, NK cells were 
furthermore sorted into CD56brightNKG2A+ NK cells 
CD56brightNKG2A− and CD56dim NK cells, and B cells were 
into naïve B cells (CD3−CD20+CD38−CD27−), centrocytes 
(CD3−CD20+CD38+CD27+/− and small size), centroblasts 
(CD3−CD20+CD38+ CD27+/− and bigger size) and memory/ 
plasmablasts (combining non-switched, switched memory 
B cells and plasmablasts). Detailed gating strategies 
applied for B and NK cell sorting are represented in 
Figures 1A and 1B and 2A. Throughout this study, purity 
of cell isolates was > 97 % for all experiments.
B cell transformation/infection assays
The transformation assay was performed as 
described previously [13]. In NK co-cultures 1’500 
sorted NK cells were added to 100’000 B cells to mimic 
physiologic proportions in tonsils (ET ratio 1:40) as 
previously established [13]. Non-virus inoculated samples 
as well as NK-cell free cultures served as controls for 
infection as well as restriction rates. The infection assay 
was adapted from the transformation assay [13]. Cells 
were kept in culture for 18, 24, 38, 44 or 72 h. GFP 
expression was analysed via flow cytometry (FACSCanto 
II, BD). Restriction of infection was calculated with the 
adapted formula described previously for restriction of 
transformation [13], i.e. Percentage of restriction of B cell 
infection = (1 - total GFP + B cells of sample with NK cells/ 
total GFP + B cells of sample without NK cells) × 100. 
For blocking experiments, applicable cells were treated as 
described before [52]. Briefly, cells were preincubated for 
1 hour with 10 μg/ml neutralizing antibodies: α-CD337 
(NKp30), α-HLA-A, -B, -C, α-IFN-γ or α-CD336 (NKp44) 
(all BioLegend) or with isotype controls α-IgG1Κ and 
α-IgG2a (eBioscience). Cells were (co-)cultured for 72 h 
and infection status of B cells as well as B cell survival 
rates were determined by flow cytometry. 
For the IFN-γ dose-response assay, flow sorted 
tonsil-derived B cells of 5 donors were plated à 
1 × 105 cells per well in a flat-bottom 96-well plate. 
After inoculation with 0.5 MOI of recombinant EBV 
cells were cultured for 12 d, 0 h, 18 h, 2 d, 3 d, 4 d or 
10 d after inoculation different amounts of recombinant 
human IFN-γ (rhIFN-γ, BioLegend) were added. To 
prevent starvation, cells were fed at days 4 and 8 with 
50 µL R10. 
Flow cytometry, data analysis and statistics
General gating strategy for live cells: lymphocyte 
population in forward/sideward scatter (FSC/SSC), live 
(Aqua-) cells. All flow cytometry data analysis was 
performed with FlowJo Version ×.0.7. For statistical 
evaluation and representation of data we used GraphPad 
Prism software Version 10. Unpaired t-test, regular 
ANOVA Tukey-corrected for multiple comparisons were 
applied as indicated in the figure legends, and p-value 
≤ 0.05 was defined as statistically significant. Error bars 
in the graphs and figures represent the standard error of 
the mean (SEM).
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